Alliqua sees Q3 revenue $4.85M, consensus $4.73M
While the Company has not finalized its full financial results for the nine month period ended September 30, 2016, it expects third quarter total revenue from continuing operations of approximately $4.85M compared to $4.19M last year, representing growth of approximately 16% year-over-year. The Company further estimates that sales of products were $4.35 million and that contract manufacturing sales were approximately $500,000 for the third quarter of 2016. Product revenue for the third quarter of 2016 represents growth of approximately 19% on both a year-over-year and on a quarter-over-quarter basis."We are extremely pleased with our third quarter revenue results, led by continued commercial progress within our biologics franchise and a record quarter for MIST Therapy," said David Johnson, Chief Executive Officer of Alliqua BioMedical. "We look forward to sharing our full financial and operating results during our investor call on November 4th."